Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 12056.145 | uM | inf | inf | 0.9538 | 0.9538 | 0.0000 | 0.0958 | 0.3538 | 0.8365 | |
MX1 | Unknown | Unknown | Nilotinib | ABL | nRTK | 10644.145 | uM | 3.15010 | 3.71960 | -0.5688 | -0.4876 | 4.0955 | 0.4971 | 0.9711 | 0.4300 | |
HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 11055.145 | uM | inf | inf | 0.9791 | 0.9791 | 0.0000 | -0.0257 | -0.8188 | 1.7616 | |
SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 10875.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0427 | -3.3446 | 0.7643 | |
HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 12112.145 | uM | inf | inf | 0.9353 | 0.9353 | 0.0000 | 0.0338 | 0.0179 | 1.9247 | |
AU565 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 10880.145 | uM | inf | inf | 0.9804 | 0.9804 | 0.0000 | 0.0621 | 0.0247 | 1.4751 | |
SUM185PE | TNBC | Luminal | Nilotinib | ABL | nRTK | 12269.145 | uM | inf | inf | -0.2047 | -0.2047 | 0.0000 | 0.3187 | 0.1533 | 0.4894 | |
SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 10579.145 | uM | inf | inf | 0.7382 | 0.7382 | 0.0000 | 0.1219 | 0.2766 | 1.0664 | |
SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 11852.145 | uM | inf | inf | 1.0081 | 1.0081 | 0.0000 | 0.0183 | 0.1759 | 1.5550 | |
SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 10695.145 | uM | 62.26220 | 195.72340 | -0.0440 | -1.0000 | 0.9592 | 0.1519 | 0.9262 | 1.1360 | |
HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 10996.145 | uM | inf | inf | 1.0142 | 1.0142 | 0.0000 | 0.0557 | 0.1140 | 0.5765 | |
HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 12192.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0217 | -0.1880 | 0.4175 | |
BT-483 | HR+ | Luminal | Nilotinib | ABL | nRTK | 10696.145 | uM | inf | inf | 0.6817 | 0.6817 | 0.0000 | 0.2546 | 0.0751 | 0.3316 | |
HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 10753.145 | uM | 410.88640 | 1000.00000 | 0.5140 | -0.1122 | 0.2277 | 0.1893 | 0.7339 | 1.5180 | |
HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 12000.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0614 | 0.0000 | 0.6084 | |
HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 11936.145 | uM | inf | 2.17830 | 0.5045 | 0.5364 | 5.0000 | 0.1750 | 0.8994 | 0.8451 | |
BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 12291.17 | uM | inf | inf | 0.6458 | 0.6458 | 0.0000 | 0.2392 | 0.3142 | 0.5585 | |
BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 12178.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0369 | 0.0948 | 0.6127 | |
HCC38 | TNBC | Basal B | Nilotinib | ABL | nRTK | 10578.145 | uM | 74.17850 | 26.03660 | 0.4519 | 0.4436 | 2.0847 | 0.1179 | 0.9504 | 1.6766 | |
184A1 | NM | Basal | Nilotinib | ABL | nRTK | 12509.17 | uM | inf | 0.16976 | 0.8260 | 0.8615 | 1.0340 | 0.0781 | 0.8007 | 1.3955 | |
184B5 | NM | Basal | Nilotinib | ABL | nRTK | 12566.17 | uM | inf | 0.08710 | 0.9223 | 0.9254 | 0.8046 | 0.0464 | 0.8541 | 1.4648 | |
HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 10693.145 | uM | 13.06880 | 9.64330 | 0.2012 | 0.3906 | 5.0000 | 0.1556 | 0.8568 | 0.8492 | |
LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 12319.17 | uM | inf | inf | 0.9335 | 0.9335 | 0.0000 | 0.1304 | 0.1701 | 0.4684 | |
ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 11660.145 | uM | inf | 8.21380 | 0.6802 | 0.7742 | 4.9993 | 0.0697 | 0.7382 | 0.9169 | |
ZR-75-1 | HR+ | Luminal | Nilotinib | ABL | nRTK | 12003.145 | uM | inf | inf | 0.9728 | 0.9728 | 0.0000 | 0.0104 | 0.0000 | 0.9611 |